Research Article
Body Composition Analysis of 10 Years versus 5 Years of Adjuvant Endocrine Therapy in Patients with Nonmetastatic Breast Cancer
Table 1
Patients baseline characteristics.
| | | Patients with 5 years of adjuvant endocrine therapy (n = 45) | Patients with 10 years of adjuvant endocrine therapy (n = 45) | value |
| | Age (median) | 62.5 | 62.8 | 0.521 |
| | Weight (kg) | 72.2 | 72.6 | 0.529 |
| | BMI (kg/m2) | 26.1 | 26.3 | 0.809 |
| | Muscle mass index (cm/m2) | 61.5 | 64.1 | 0.217 |
| | Visceral adipose index (cm/m2) | 25.1 | 26.9 | 0.176 |
| | Tumor size | | | | | T1 | 37 | 32 | | | T2 | 8 | 13 | |
| | Lymphatic invasion | | | | | N0 | 35 | 33 | | | N1 | 10 | 12 | |
| | Number of metastatic lymph nodes | | | | | M0 | 45 | 45 | |
| | ER/PE status | | | | | ER+/PR+ | 30 | 27 | | | ER+/PR− | 9 | 6 | | | ER−/PR+ | 6 | 7 | | | ER−/PR− | 0 | 5 | |
| | Her-2 status | | | | | Positive | 15 | 23 | | | Negative | 30 | 22 | |
| | Adjuvant endocrine therapy | | | | | Anastrozole | 8 | 7 | | | Letrozole | 13 | 16 | | | Tamoxifen | 12 | 10 | | | Exemestane | 12 | 12 | |
| | Previous chemotherapy | | | | | Doxorubicin + cyclophosphamide | 19 | 18 | | | Docetaxel + cyclophosphamide | 19 | 22 | | | Docetaxel + carboplatin | 7 | 5 | |
| | Target therapy (transtuzumab) | | | | | Yes | 15 | 21 | | | No | 30 | 24 | |
| | Surgery | | | | | Modified radical mastectomy | 11 | 13 | | | Breast conservation | 34 | 32 | |
|
|
BMI: body mass index; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor 2.
|
